The study targets patients aged 22 to 60 who have not responded to conservative treatments for femoral condyle or trochlear cartilage lesions. Surgeons Juan Osorio and Emilio Tufiño will lead the clinical team, with Osorio serving as principal investigator. The data collected in Panama, combined with ongoing recruitment efforts in Ontario following Health Canada authorization, will underpin the company’s broader regulatory strategy.

Chondrograft functions as a minimally invasive bridge, offering immediate mechanical stability alongside long-term regenerative potential. The device has already secured Breakthrough Device Designation from the U.S. Food and Drug Administration. According to CEO Ben Holmes, the company chose Panama for its efficient regulatory framework and robust clinical infrastructure, viewing the site as a vital launchpad for bringing orthopedic innovation to the global market.